BD has picked a new executive to lead its planned connected care segment, as the company nears the conclusion of its ...

Researchers at Johns Hopkins University have shown that an artificial intelligence-powered robot—trained on videos of ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...

Nuclidium has raised 79 million Swiss francs ($99 million) as the Swiss and German biotech looks to continue the clinical ...

Analysts are keeping the faith in Ultragenyx’s brittle bone disease medicines despite the monoclonal antibody failing to score an early outright win in an ongoing phase 3 trail. | Analysts are keeping ...

AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner, Eolas T | ...

Novartis has inked a deal with China-based biotech Sironax that gives the pharma the exclusive option to acquire the ...

Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which ...

At the halfway mark last year, 97 layoff rounds were reported, marking a 32% year-over-year increase for the first half of ...

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...

Rhythm Pharmaceuticals’ push to move obesity patients from jabs to tabs has stayed on beat. | Rhythm Pharmaceuticals’ push to ...